Market Closed -
Nasdaq
16:00:00 2024-05-15 EDT
5-day change
1st Jan Change
4.54
USD
+0.89%
0.00%
-26.42%
OmniAb, Inc.(NasdaqGM:OABI) dropped from Russell 2500 Growth Index
June 23, 2023 at 12:00 am
OmniAb, Inc.(NasdaqGM:OABI) dropped from Russell 2500 Growth Index
Earnings Flash (OABI) OMNIAB Reports Q1 Revenue $3.8M, vs. Street Est of $5.9M
05-09
MT
OmniAb, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-09
CI
Transcript : OmniAb, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09
OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing
03-25
MT
Sector Update: Health Care Stocks Gain Pre-Bell Thursday
03-21
MT
OmniAb Swings to Q4 Loss, Revenue Declines
03-20
MT
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M
03-20
MT
Transcript : OmniAb, Inc., Q4 2023 Earnings Call, Mar 20, 2024
03-20
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
03-20
CI
OmniAb, Inc.(NasdaqGM:OABI) added to NASDAQ Biotechnology Index
12-18
CI
OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference
12-14
CI
Omniab Insider Bought Shares Worth $1,010,000, According to a Recent SEC Filing
12-13
MT
RBC Initiates OmniAb at Outperform With $6 Price Target, Says Stock Gives Exposure to Growth Potential of Monoclonal Antibody Therapies
11-29
MT
Omniab Insider Bought Shares Worth $405,517, According to a Recent SEC Filing
11-13
MT
Transcript : OmniAb, Inc. - Special Call
11-09
OmniAb, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-09
CI
Earnings Flash (OABI) OMNIAB Posts Q3 Revenue $5.5M, vs. Street Est of $10.3M
11-09
MT
Omniab, Inc. Appoints Steve Love to Its Board of Directors and as Audit Committee Chair, Member of the Human Capital Management and Compensation Committee
11-01
CI
A Collaborative Scientific Team Led by Researchers At the Applied Biomedical Science Institute, Scripps Research, Kansas State University, University of Louisville, Omniab, Inc., and Ligand Pharmaceuticals Discovers and Validates Potential New Class of Therapeutic Agent Based on the Unique Antigen Binding Regions of Cow Antibodies
23-09-20
CI
Insider Buy: Omniab
23-08-15
MT
OmniAb, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Transcript : OmniAb, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
Earnings Flash (OABI) OMNIAB Posts Q2 Revenue $6.9M, vs. Street Est of $11.9M
23-08-10
MT
Omniab Announces the Passing of Director Sunil Patel
23-08-07
CI
Hillstream Expands Collaboration With Minotaur, License Deal With OmniAb to Develop Cancer Treatments; Shares Rise
23-07-20
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Companyâs OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
More about the company
Last Close Price
4.54
USD
Average target price
9.875
USD
Spread / Average Target
+117.51%
Consensus
1st Jan change
Capi.
-26.42% 529M +29.77% 49.18B +1.00% 42.11B +50.47% 40.37B -5.26% 28.85B +13.68% 26.09B -22.99% 18.71B +8.22% 13.26B +32.41% 12.32B -1.62% 11.99B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
OMNIAB, INC. 
